Company Overview and News
Activision Blizzard stock was down on Monday despite the company announcing good news about Call of Duty: Black Ops 4.
A late-afternoon bounce in U.S. equities helped lift investors’ spirits, but doubts still linger as key indices hang near their 200-day moving averages and as tech continues to struggle ahead of earnings season. Here are our top stock trades to start the week.
BAC GS SCHW JPM JNJ ATVI
On today’s episode of Free Lunch, Ryan McQueeney recaps morning news from Wall Street, including tensions between the U.S. and Saudi Arabia, big bank earnings, and historic data from Activision Blizzard. The host also covers the bankruptcy of Sears, September’s retail sales results, and holiday shopping expectations.
WFC WFCNP BAC C ATVI BAC SHLD SHLDW
NEW YORK (AP) — U.S. stocks are mixed Monday as technology companies continue to slump and the Commerce Department said retail sales remained sluggish in September. The S&P 500 and other major U.S. indexes are coming off their worst week since late March as investors worry about rising interest rates and trade tensions between the U.S. and China. Bank of America dropped after it reported disappointing growth in loans.
DLTR NDAQ HRS ATVI
Bank of America – The bank reported profit of 66 cents per share, beating consensus estimates by 4 cents a share. Revenue also exceeded forecasts. The bank's bottom line was helped by higher interest rates and last year's corporate tax cut.
SHLD DLTR DVMT RL SHLDW HRS ATVI
UBSFY EA UBSFF ATVI
Stocks were indicated flat to marginally higher on Monday after last week’s sell-off was slightly tempered by Friday’s rally. While the all-time highs are still within striking distance, investors have seen lower upside from buying immediately after the big market pullbacks in 2018 than in prior years. Now those investors also have to consider how to position their investments for the rest of the year and into 2019.
WFCNP ARRS ACRX ATVI CLF DLPH AEO LULU ELAN MS WFC ABUS TRI MRO
2018-10-13 investorplace - 1
We have all heard about the big stocks to buy a million times. That’s not to say they are bad investing prospects. Not at all. Amazon (NASDAQ:AMZN), for example, is an expensive stock with robust growth potential.
SPLK KKR TRUP SLDB GLMD SRPT PE MOMO ATVI MRNS GTN AMZN
Take-Two Interactive Software (TTWO - Free Report) recently announced that it will launch Borderlands 2 VR on Dec 14. The virtual reality version of the “shooter-looter” franchise will be available on Sony’s PlayStation VR for $49.99. Like the original game, Borderlands 2 VR will be based in Pandora and include four playable vaults namely – Salvador, Maya, Axton and Zer0. Players pre-ordering Borderlands 2 VR get instant access to a dynamic PlayStation Theme featuring these vaults.
EA TTWO ATVI
Comcast (NASDAQ:CMCSA) is playing a dangerous game of risking irrelevancy. Toward the end of last month, the Comcast stock price fell sharply. I can understand why. Management announced that it had won its bid for European pay-TV provider Sky (OTCMKTS:SKYAY). What they actually won was an eventual road to the unemployment line.
CMCSA FOXA MANU ATVI
NEW YORK: US stocks tumbled for a second straight session on Thursday (Oct 11) as volatility reigned on Wall Street amid worries about higher interest rates and trade wars.
NEW YORK – U.S. stocks tumbled for a second straight session on Thursday as volatility reigned on Wall Street amid worries about higher interest rates and trade wars.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ATVI / Activision Blizzard, Inc. on message board site Silicon Investor.
|Activision....Returns!||Activision....Returns!||Activision....Returns!||Latvian Forest||Latvian Forest||Latvian Forest|
as of ET